Introduction {#sec1-1}
============

The canine glaucomas are defined as a group of ocular diseases whose common feature is the death of the retinal ganglion cells, associated with an increase in intraocular pressure (IOP) (Plummer *et al.*, 2013). Elevated IOP occurs when the egress of aqueous humor through the conventional outflow pathway is impeded (Plummer *et al.*, 2013). Canine glaucomas are usually divided into primary, secondary or congenital glaucoma (Plummer *et al.*, 2013). Primary glaucoma (PG) is defined as an elevated IOP with no other concurrent eye disease. It can affect both eyes simultaneously or asynchronously, and exhibits a breed predisposition (Read *et al.*, 1998; Wood *et al.*, 1998; Bjerkas *et al.*, 2002; Kato *et al.*, 2006; Strom *et al.*, 2011; Plummer *et al.*, 2013; Boillot *et al.*, 2014; Fricker *et al.*, 2016; Bedford, 2017). Structural abnormality of the conventional outflow pathway comprising the pectinate ligament, the uveal and corneoscleral trabecular meshworks and the ciliary cleft (Read *et al.*, 1998; Wood *et al.*, 1998; Bjerkas *et al.*, 2002; Kato *et al.*, 2006; Strom *et al.*, 2011; Plummer *et al.*, 2013; Fricker *et al.*, 2016; Bedford, 2017), or an abnormal biochemical metabolism of the trabecular meshworks (Hassel *et al.*, 2007; Weinstein *et al.*, 2007; Mackay *et al.*, 2008a, 2008b;), may be responsible for PG. Many surgical techniques have been described to manage PG, acting either on the production (De Roetth, 1965; Brightman *et al.*, 1982; Hardman and Stanley, 2001; Lutz and Sapienza, 2009a; Azoulay *et al.*, 2011; Harrington *et al.*, 2013) or the egress of aqueous humor (Cullen *et al.*, 1998; Cullen, 2004), or both at the same time (Sapienza and van der Woerdt, 2005; Lutz and Sapienza, 2009b; Amagai *et al.*, 2014).

Cyclocryothermy (De Roetth, 1965; Brightman *et al.*, 1982), transscleral cyclophotocoagulations (TSCP) (Hardman and Stanley, 2001; Sapienza and van der Woerdt, 2005; Amagai *et al.*, 2014) and endocyclophotocoagulation (ECP) (Lutz and Sapienza, 2009a,b; Azoulay *et al.*, 2011; Harrington *et al.*, 2013) are the most common cyclodestructive techniques. Cyclocryothermy consists of non-selectively freezing the ciliary process with a nitrous oxide or liquid nitrogen probe applied in direct contact with the bulbar conjunctiva, overlying to the ciliary processes (De Roetth, 1965; Brightman *et al.*, 1982). This technique has become progressively obsolete and was mainly used to reduce IOP in blind patients with persistent pain. Transscleral diode or Nd: YAG laser cyclophotocoagulations have been studied in veterinary medicine (Hardman and Stanley, 2001; Sapienza and van der Woerdt, 2005; Amagai *et al.*, 2014). They aim to destroy the ciliary processes with focused laser energy. As with cyclocryothermy, the probe is applied trans-sclerally through the bulbar conjunctiva over the ciliary processes. Although the duration of effect on the normalization of the IOP remains variable with these techniques, TSLCP remains widely used in the management of PG. ECP is a more recent technique which aims to selectively destroy the ciliary processes via an intraocular approach (Lutz and Sapienza, 2009a,b; Azoulay *et al.*, 2011; Harrington *et al.*, 2013). Although it requires further studies to implement standardized procedures, ECP seems a promising surgery. Anterior chamber shunt implantations are the leading techniques aiming at facilitating the outflow of aqueous humor. The purpose of these shunts is to create a new discharge chamber, bypassing the abnormal conventional outflow pathways. As for the cyclodestructive surgeries, many different procedures and materials have been described to facilitate aqueous humor drainage, with varying results (Cullen *et al.*, 1998; Cullen, 2004; Sapienza and van der Woerdt, 2005; Lutz and Sapienza, 2009b). Glaucoma surgeries, used alone or in combination, offer a maximum duration effect of several months to one or two years (Plummer *et al.*, 2013). Dose-effect relationship remains difficult to predict with the current cyclodestructive techniques. Consequently, severe complications such as IOP rebound spike, chronic inflammation, cataract formation, phtisis bulbi and corneal ulcers, are frequent (De Roetth, 1965; Brightman *et al.*, 1982; Hardman and Stanley, 2001; Sapienza and van der Woerdt, 2005; Lutz and Sapienza, 2009a,b; Azoulay *et al.*, 2011; Harrington *et al.*, 2013; Amagai *et al.*, 2014). High intensity focused ultrasound (HIFU) aims to selectively destroy the ciliary process, using ultrasonic energy instead of the light energy provided by Laser technologies. The use of HIFU in the treatment of glaucoma in humans was first described in the eighties with promising results (Coleman *et al.*, 1985a,b, 1986; Burgess *et al.*, 1986). Temporarily abandoned because of the size of the device and the time required for the procedure, HIFU has recently sparked again the interest of ophthalmologists (Aptel *et al.*, 2011, 2014b, 2016; Denis *et al.*, 2015). Evolution of the technologies led to the manufacturing of smaller and more efficient devices, allowing safer and shorter procedures (Charrel *et al.*, 2011). The purpose of the present study was to evaluate the efficacy and safety of HIFU in dogs with PG.

Materials and Methods {#sec1-2}
=====================

Animal recruitment {#sec2-1}
------------------

Seven dogs with PG of one or both eyes at the Ophthalmology Department of the Centre Hospitalier Vétérinaire Saint-Martin (Saint-Martin Bellevue, France), were included in the study. All dogs underwent a complete ophthalmic examination (Slit Lamp, STT), an IOP measurement (Tonovet^®^, Icare, Finland), ultrasound biomicroscopy (UBM) with a 35 MHz probe (VuMax^®^, Sonomed Escalon, EDC LAMY, Carvin, France), and conventional ultrasound examination of the posterior segment with a 20 MHz probe (VuMax^®^, Sonomed Escalon, EDC LAMY, Carvin, France). In patients with a clear cornea, non-mydriatic indirect ophthalmoscopy and gonioscopy were also performed. Inclusion criteria were dogs with a raised IOP (≥ 21 mm Hg) and a narrow or closed ciliary cleft as observed by UBM and/or gonioscopy with no concurrent anomaly of the posterior segment as observed by conventional 20 MHz ultrasound. Exclusion criteria were any other identifiable causes of secondary glaucoma.

HIFU device {#sec2-2}
-----------

The HIFU device used in this study was adapted from a human device that has previously been described (Aptel *et al.*, 2010; Charrel *et al.*, 2011). The EYE TECH CARE Company (Rillieux-la-Pape, France) modified the machine for veterinary use. It was then composed of a coupling cone made of polymer filled with saline solution, centered on the cornea in contact with the patient's conjunctiva. A probe containing an active piezoelectric element was inserted in the upper part of the coupling cone and immersed in the saline solution. The transducer containing the piezoelectric ceramic was a segment of a 10.2 mm radius cylinder with a 4.5 mm width and a 7 mm length. The focal volume of the transducer had an approximately elliptic cylinder shape. The position of the ceramic into the probe was defined to accurately fit with the canine eye anatomy (data provided by the manufacturer). Thus, the ultrasound beam emitted by the probe was selectively targeted on the ciliary processes of the canine patient to be treated. The resonant frequency of the transducer was 21 MHz.

Surgical procedure {#sec2-3}
------------------

Meloxicam was administered intravenously prior to surgery to limit intraocular inflammation associated with the surgery. Topical anesthesia was achieved by 5 consecutive instillations of oxybuprocaine chlorhydrate (Cébésine^®^ 0.4 %, Chauvin, Montpellier, France) at 30 second intervals. General anesthesia was induced by IV injection of medetomidine (2 μg/kg) (Domitor^®^, Vetoquinol, Lure, France), ketamine (5 mg/kg) (Imalgene^®^, Merial, Lyon, France), and morphine (0.3 mg/kg) (Lavoisier, Paris, France), followed by inhalation of isoflurane gas (1.5 to 3% of an air mixture of 30% - oxygen 70%) (Vetflurane^®^, Virbac, Carros, France). The anaesthetised dog was positioned in dorsal or lateral recumbency with its head stabilized in a hollow cushion, as for an intraocular surgery. The combination probe / coupling cone of the HIFU device was available in three sizes (16, 18, 20 mm), corresponding to the different sizes of eyeballs to be treated. The operator selected the coupling cone size matching the palpebral aperture of the patient being treated ([Fig. 1A](#F1){ref-type="fig"}). Once the coupling cone was centered on the patient's cornea, it was manually held by the operator. The corresponding probe was then inserted in the upper part of the cone ([Fig. 1B](#F1){ref-type="fig"}). The cavity created between the eye surface of the patient, the edge of the coupling cone and the probe was filled with 5 mL of sterile saline, through the central aperture of the device ([Fig. 2](#F2){ref-type="fig"}).

![(A): Coupling cone inserted into the palpebral fissure of the patient being treated. The aperture of the coupling cone had to be centered on the cornea so that the ultra sound beam reached precisely the ciliary processes. (B): General view of the device.](OpenVetJ-8-305-g001){#F1}

![(A): Schematic cross section of the High Intensity Focused Ultrasound device. The veterinary probe contains only one transducer. (B): Schematic representation of the focal volume associated with the piezoelectric ceramic.](OpenVetJ-8-305-g002){#F2}

All patients were treated with the transducer activated for 5 seconds at 2.4 W acoustic power. Eyes were divided in three groups, depending on the preoperative IOP: Group 1 with IOP ranging from 21 to 30 mm Hg, Group 2 with IOP ranging from 31 to 40 mm Hg and Group 3 with IOP higher than 40 mm Hg. As the time of ultrasound delivery could not be set with the veterinary device and fixed to 5 seconds, it was arbitrarily decided to increase the number of treated sites in relation to the degree of preoperative IOP elevation. We assumed that the number of treated sites would correlate to the effect on the IOP, as would the time of ultrasound delivery (Denis *et al.*, 2015). In each group a specific number of sites were thus treated: 6 sites for group 1, 8 sites for group 2 and 10 sites for group 3, avoiding the 3 o'clock and the 9 o'clock positions to prevent direct damage to the long posterior ciliary blood vessels (Brightman *et al.*, 1982).

Both eyes of patients bilaterally affected were treated during the same session. Patients of the study were hospitalized for 24 hours. The IOP was measured at 6h and 24h postoperatively during the hospitalization period. At each IOP measurement, a complete ophthalmic examination was performed to identify potential side effects associated with the procedure. In all eyes, the post-operative treatment consisted of topical dorzolamide / timolol maleate combination BID (Cosopt^®^, MSD, Courbevoie, France), topical latanoprost BiD (Xalatan^®^, Pfizer, Paris, France) and systemic meloxicam 0.1 mg/kg (Metacam^®^, Boehringer Ingelheim, Paris, France) for one week.

Follow-up {#sec2-4}
---------

Follow-up examinations were performed at 7, 21, 90 and 180 days post-surgery and consisted of a complete ophthalmic examination and IOP measurement. Topical medical treatment was continued until the end of the follow-up period.

End point and statistical analysis {#sec2-5}
----------------------------------

Surgical success was defined as an IOP less than or equal to 20 mm Hg, with no clinical signs of ocular pain at the last follow-up examination. All IOP data were expressed as median and min, max values. Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Normality of data was assessed using Shapiro-Wilk normality tests. Considering the non-Gaussian distribution of the data and the small number of animals per group, treatment group and time effects were assessed using the non-parametric Friedman test. Post hoc analysis was conducted with Dunn's test. P-values \< 0.05 were considered statistically significant.

Results {#sec1-3}
=======

Patients' characteristics {#sec2-6}
-------------------------

An overview of the 7 patients in which the HIFU cyclocoagulation was used is presented in [Table 1](#T1){ref-type="table"}, showing breed, gender, age, affected eye, ongoing anti-glaucomatous therapies prior to referral, IOP at initial presentation and evaluation of dazzle reflex and menace response.

###### 

Summary of patient data with regards to breed, gender, age, affected eye, ongoing preoperative treatment, Intra Ocular Pressure at initial presentation, vision tests results, and corresponding groups.

  Breed                     Gender                                        Age   Affected eye   Medical treatment prior to referal            IOP at initial presentation   Dazzle Reflex   Menace response   Corresponding group   Eye \#
  ------------------------- --------------------------------------------- ----- -------------- --------------------------------------------- ----------------------------- --------------- ----------------- --------------------- --------
  Jack Russel Terrier       M                                             9     OD             Dexamethasone                                 23                            1               1                 1                     Eye 1
  OS                        Dexamethasone                                 51    1              0                                             3                             Eye 12                                                  
  Siberian Husky            M                                             7     OD             Timolol Maleate                               24                            1               1                 1                     Eye 2
  OS                        Timolol Maleate                               21    1              1                                             1                             Eye 3                                                   
  French Bulldog            NF                                            1     OS             Pilocarpine                                   22                            1               1                 1                     Eye 4
  OD                        Pilocarpine                                   31    1              1                                             2                             Eye 9                                                   
  American Cocker Spaniel   F                                             11    OD             Timolol Maleate                               28                            1               1                 1                     Eye 5
  OS                        Timolol Maleate                               21    1              1                                             1                             Eye 6                                                   
  Labrador Retriever        M                                             7     OS             Timolol Maleate, Dorzolamide                  28                            1               1                 1                     Eye 7
  OD                        Timolol Maleate, Dorzolamide                  59    1              0                                             3                             Eye 13                                                  
  Shiba Inu                 NF                                            7     OS OD          Timolol Maleate, Dorzolamide, 41Latanoprost   34                            1               1                 2                     Eye 8
  OD                        34Timolol Maleate, Dorzolamide, Latanoprost   41    1              1                                             3                             Eye 11                                                  
  French Bulldog            M                                             8                    No treatment                                  34                            1               1                 2                     Eye 10

(M): Male; (NF): Neutered Female; (F): Female; (OD): Right Eye; (OS): Left Eye; (IOP): Intraocular Pressure.

A series of 13 eyes from 7 dogs was included in the study. The mean age of affected dogs was 7 years, ranging from 4 to 11 years. Six different breeds were represented. There were 4 males and 3 females. The procedure was performed in both eyes in 6 patients and in the right eye in one. Ongoing ocular treatment prior to referral included beta-blockers, carbonic anhydrase inhibitors, prostaglandins analogs and pilocarpine. Four eyes had mixed treatment. One eye had no treatment prior to referral. Median IOP prior to the surgery was 28 mm Hg (min 21 mm Hg and max 59 mm Hg)

Safety and efficacy of the procedure {#sec2-7}
------------------------------------

There were no intraoperative complications during the procedure. One dog (the Shiba Inu) encountered an ocular hypertensive spike in both eyes during the first hours post-surgery (baseline IOP + 13 mm Hg in OD and baseline IOP + 7 mm Hg in OS). This patient underwent a new HIFU procedure with a particular attention to the probe positioning. No signs of pain were visible during the immediate post-operative period except for the patient with an ocular hypertension spike, which presented with epiphora and blepharospasm.

Transient conjunctival hyperaemia was visible in 2 eyes from group 2 (66%) and in all eyes from group 3. Well circumscribed conjunctival burns corresponding to the treated sites were visible in 2 eyes from group 3 (66%). Those immediate postoperative complications resolved with additional vaseline ointment (Pommade Vitamine A Dulcis, Allergan, Pringy, France) and were no longer visible at the first follow-up examination at day 7. Median, min, max and relative IOP reductions of each group and of all patients are shown in [Table 2](#T2){ref-type="table"}.

###### 

Median, Min-Max and relative IOP reductions of each group (mm Hg: Millimeters of Mercury, IOP: Intra Ocular Pressure, H: hours, D: Day, Mo: Month).

  Time       Group 1, n = 7 eyes   Group 2, n = 3 eyes   Group 3, n = 3 eyes                                
  ---------- --------------------- --------------------- --------------------- ------------- -------------- -------------
  Baseline   23 \[21-28\]          \-                    34 \[31-34\]          \-            51 \[41-59\]   \-
  6 H        24 \[11-28\]          13.2 ± 23.4           30 \[24-41\]          4.0 ± 25.0    44 \[37-54\]   6.4 ± 35.1
  24 H       13 \[9-24\]           38.8 ± 16.0           19 \[16-19\]          45.3 ± 7.2    28 \[11-28\]   56.9 ± 14.5
  D 7        14 \[9-22\]           43.2 ± 13.1           18 \[14-19\]          48.3 ± 9.2    22 \[14-24\]   60.5 ± 6.7
  D 21       14 \[10-22\]          41.3 ± 12.1           21 \[11-21\]          46.0 ± 18.9   22 \[14-24\]   60.5 ± 6.7
  Mo 3       16 \[9-25\]           36.0 ± 21.5           17 \[13-26\]          43.5 ± 19.2   24 \[15-27\]   56.6 ± 8.5
  Mo 6       10 \[9-16\]           49.7 ± 14.4           14 \[9-21\]           55.5 ± 17.7   14 \[11-19\]   70.7 ± 7.1

Effect of the treatment group on the IOP {#sec2-8}
----------------------------------------

There was a significant global effect of the treatment group on IOP reduction when comparing the 3 groups (p\<0.0001), supporting that IOP reduction is a function of the initial level of IOP and the number of treatment sites. Multiple comparisons reveal a higher IOP decrease in group 3 compared to group 1 (p=0.0009), meaning that the greater the number of treated sites, the greater the lowering effect on IOP.

Effect of the sonication procedure over time {#sec2-9}
--------------------------------------------

There was a significant decrease of IOP after treatment in group 1 (p=0.0003). IOP decrease in group 2 and 3 did not reach statistical significance.

[Figure 3](#F3){ref-type="fig"} illustrates the evolution of IOP over time for each group. Long term post-operative evaluation of vision was consistent with preoperative data in all patients with no visual deterioration at the completion of the follow-up period.

![Evolution of Intraocular pressure over time for each group.](OpenVetJ-8-305-g003){#F3}

Discussion {#sec1-4}
==========

The aim of the present study was to evaluate the hypotensive effect of HIFU delivered by a miniaturized transducer on the ciliary processes of dogs affected by PG. The use of HIFU in the treatment of refractory glaucoma was described in humans in the eighties (Coleman *et al.*, 1985a,b, 1986; Burgess *et al.*, 1986). Although it showed a promising IOP reduction in glaucomatous patients, this technique was progressively abandoned. The equipment needed was bulky, the time of the procedure was long (up to 2 hours), and the rate of ocular complications was relatively high, probably due to the low frequency of the original device (5 MHz) and the inaccuracy of the probe positioning.

The technology providing the HIFU was recently optimized and modernized (EYE TECH CARE, Rillieux la Pape, France) with a miniaturized device adapted to the anatomy of the human eye. It is available in three different sizes and allows a shorter treatment time of approximately 2 minutes at a higher frequency (21MHz) (Charrel *et al.*, 2011). It was further modified by the manufacturer for canine ocular anatomy, so that the ultrasound beam was focused precisely on the ciliary processes. For economic reasons, the veterinary prototype consisted of a single piezoelectric ceramic (vs 6 in the human device) thus treating one site at a time. Furthermore, the duration of US delivery can be set in the human device, whereas it was fixed to 5 seconds in the veterinary one.

The mechanism leading to IOP reduction has been assessed by histologic and UBM imaging studies on animals and humans (Valtot *et al.*, 1990; Polack *et al.*, 1991; Aptel *et al.*, 2010, 2014a). Coagulative necrosis (loss of ciliary epithelium, vascular congestion, distension of the collagen fibers) and secondary cystic involution of the ciliary bodies are the main consequences of focused ultrasounds, thus resulting in decreased aqueous humor production. Hyporeflective suprachoroidal spaces were also observed postoperatively by UBM in human patients and in rabbits, suggesting increased uveoscleral outflow through the suprachoroidal space (Aptel *et al.*, 2011, 2014a). When properly targeted over the ciliary body, the focused ultrasound beam does not damage the adjacent ocular structures or produce intraocular inflammation (Aptel *et al.*, 2010), consistently with our clinical findings which did not reveal any postoperative intraocular inflammation.

The procedure was overall well tolerated in canines. Ocular pain was observed in one patient, who also experienced bilateral ocular hypertension. As the other patients did not exhibit signs of pain or hypertensive spikes, we hypothesized that pain was linked to the elevated IOP and not with the procedure itself. The cause of the rebound effect (RE) after sonication remains unknown and seems unusual in humans (Aptel *et al.*, 2011, 2014b, 2016; Denis *et al.*, 2015). RE has been described in 92% of dogs after cyclophotocoagulation (Hardman and Stanley, 2001) whereas it was only observed in 10% of cases after cyclophotocoagulation associated with an Ahmed gonioimplantation (Sapienza and van der Woerdt, 2005). RE was probably secondary to acute iatrogenic inflammation associated with cell damage (Hardman and Stanley, 2001) and may be reduced with the use of a gonioimplant, also allowing for lower laser energy applications (Sapienza and van der Woerdt, 2005). In our study, the post-operative hypertension spike and pain were observed in the same patient, which was a Shiba Inu. These complications might be due to inadequate positioning of the probe - the small palpebral fissure of Shiba Inu dogs making access to the eye difficult. Diffuse conjunctival hyperaemia was also visible in patients from groups 2 and 3. These groups correspond to the highest levels of energy delivered to the eye, which might be responsible for diffuse conjunctival inflammation. Well circumscribed conjunctival burns were also visible in some patients. Although the ultrasound beam produced by the device was theoretically focused on the ciliary processes, there might be a localized heat dispersion leading to conjunctival lesions. Transient benign conjunctival hyperaemia was observed in humans and was more frequent in patients with higher levels of energy delivered to the eye (Denis *et al.*, 2015). Other post-operative complications reported in humans and not observed in dogs were punctate keratitis, corneal ulcer, blepharitis and discrete uveal effusions (Aptel *et al.*, 2011, 2014b, 2016; Denis *et al.*, 2015).

In human patients, a duration-effect was observed with the sonication procedure. The hypotensive effect was higher when the ceramics delivered the ultrasounds over 6 seconds than over 4 seconds (Denis *et al.*, 2015). As the duration was fixed in the veterinary probe, we decided to increase the number of sites to be treated as a function of the initial IOP. In human patients, the total amount of energy delivered to the ciliary processes depends on the number of treated sites and on the time of US delivery. The validated procedure treats 6 sites with a mean time of US delivery of 6 seconds, representing 6 x 6 s x 2.4 W = 86,4 J (Aptel *et al.*, 2011, 2014b, 2016; Denis *et al.*, 2015). In our study, the total amount of energy was 72 J for group 1, 96 J for group 2 and 120 J for group 3. Although the number of patients from group 3 was too low to reach statistical significance, our study suggests a higher IOP lowering effect in this group. To distinguish the respective roles of initial IOP level and the number of treatment sites on the IOP lowering effect, further study should evaluate the effect of the number of treatment sites in each baseline IOP ranges. The success rate of sonication for the treatment of PG was similar or better than the one of TSCP (alone (Hardman and Stanley, 2001) or combined with Ahmed valve implantation (Sapienza and van der Woerdt, 2005)) or ECP (alone (Azoulay *et al.*, 2011) or combined with a X-Press gonioimplantation (Lutz and Sapienza, 2009b)). The levels of energy delivered to the eye were comparable to TCP (Hardman and Stanley, 2001; Sapienza and van der Woerdt, 2005; Amagai *et al.*, 2014) but higher than with ECP (Lutz and Sapienza, 2009a,b; Azoulay *et al.*, 2011; Harrington *et al.*, 2013). However, the inclusion criteria were broader in our study, some eyes presenting with a smaller increase in IOP (IOP ranging from 21 to 25 mm Hg). In these eyes, the IOP normalization might also be due to the post-operative topical anti-glaucomatous treatment. Further studies are necessary to compare the ocular hypotensive effect of sonication versus medical treatment alone. It might also be interesting to evaluate the hypotensive effect of HIFU alone (i.e. without medical therapy) on normotensive canine eyes and in patients with PG. The final aim of those complementary studies would be to assess the ability of the HIFU to reduce the risk of glaucoma in normotensive eye in patients at risk (prophylactic use on the fellow eye of patients with PG, or in patients presenting with a narrow/closed ciliary cleft). Our study only assessed the influence of HIFU on the IOP in dogs with PG. Further studies are warranted to evaluate the effect of HIFU on patients with secondary glaucoma (post intraocular surgery for example).

In conclusion, our preliminary study suggests that HIFU cyclocoagulation might be a reasonable option for the management of PG in dogs. However, the number of patients included and the relatively short follow-up period preclude definitive conclusion, thus requiring larger prospective multicentric studies.
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